ABSTRACT
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very specific nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations. Here is the second version of these recommendations updated according to the evolution of knowledge on COVID19.
Subject(s)
COVID-19/epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adolescent , Adrenal Cortex Hormones/therapeutic use , Alanine/analogs & derivatives , Alanine/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/diagnosis , COVID-19 Nucleic Acid Testing , COVID-19 Vaccines/therapeutic use , Cancer Care Facilities , Child , Consolidation Chemotherapy , Drug Interactions , France/epidemiology , Humans , Induction Chemotherapy/methods , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Maintenance Chemotherapy/methods , Recurrence , Risk Assessment , Societies, Medical , COVID-19 Drug TreatmentABSTRACT
Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19.